Zinbryta Recall Recommended by European Regulators, Following Reports Of Encephalitis, Patient Deaths
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Zinbryta Brain Inflammation Risks Outweigh Benefits: EMA May 22, 2018 Irvin Jackson Add Your Comments European drug regulators confirm that the potential brain inflammation risks with Zinbryta outweigh any possible benefits that may be provided by the multiple sclerosis drug, which was recently removed from the global market amid reports of encephalitis, meningoencephalitis and other problems. In a press release issued on May 18, the European Medicines Agency (EMA) indicates that its Pharmacovigilance Risk Assessment Committee (PRAC) found that Zinbryta (dacilzumab beta) carries a risk of deadly immune system problems, which could lead the body to attack the liver, brain and other organs. Zinbryta is a multiple sclerosis injection drug that was introduced by Biogen and AbbVie in 2016. In the U.S. it was only available through a Risk Evaluation and Mitigation Strategy (REMS) program, and was recommended as a treatment for individuals who failed to respond to other first-line MS drugs, resulting in limited prescriptions over the few years it was on the market. Learn More About Zinbryta Lawsuit Worldwide Zinbryta recall issued amid reports of brain inflammation and wrongful deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Zinbryta Lawsuit Worldwide Zinbryta recall issued amid reports of brain inflammation and wrongful deaths. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In March 2018, the manufacturers announced a Zinbryta recall to phase the drug off the market, following an alarming number of reports involving severe and potentially lethal brain inflammation cases. The action came as the European Medicines Agency (EMA) moved to ban the drug amid reports of Zinbryta deaths, and at least a dozen reports of brain inflammation. The pharmaceutical companies indicate that the small number of patients using Zinbryta makes it impossible to safely and adequately characterize the number of complex and evolving adverse events linked to the drug. According to the FDA, the Zinbryta market withdrawal was completed by April 30. PRAC continued its assessment, confirming that the Zinbryta brain inflammation risks outweighed its benefits, according to the press release. “Patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected,” the press release notes. “The PRAC therefore confirmed its previous conclusions that risks of Zinbryta outweigh its benefits for patients with multiple sclerosis.” Only about 10,000 individuals worldwide have used Zinbryta, according to PRAC, highlighting the serious brain inflammation risks with at least 12 reports known to be linked to use of the drug. At least three Zinbryta deaths have been reported, all of which occurred in the United States, which led the FDA to launch an investigation into the reports. The agency was reassessing the drug’s safety profile when European regulators and the manufacturers decided the drug should be pulled from the market. Patients with questions or concerns can contact the manufacturers’ service center by calling 1-800-456-2255 or by visiting the drug website at www.zinbryta.com. The FDA also urges health care professionals and consumers to report any adverse reactions to the FDA’s MedWatch adverse event reporting program. Tags: AbbVie, Biogen, Brain Damage, Encephalitis, Meningoencephalitis, Multiple Sclerosis, Zinbryta Image Credit: | More Zinbryta Lawsuit Stories Zinbryta Risks Prevented Use As MS Drug, Despite Effectiveness of Treatment: Report April 25, 2018 Zinbryta Withdrawal from U.S. Market to Be Complete April 30 March 21, 2018 Zinbryta Recall Recommended by European Regulators, Following Reports Of Encephalitis, Patient Deaths March 8, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025) 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Zinbryta Recall Recommended by European Regulators, Following Reports Of Encephalitis, Patient Deaths March 8, 2018
Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (Posted: today) Six women have filed a joint, multiplaintiff BioZorb tissue marker lawsuit, all indicating that they suffered injuries and complications due to the recalled device’s defective design. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (05/14/2025)Four Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: yesterday) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 4 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)